Skip to main content
Premium Trial:

Request an Annual Quote

Macrogen Signs License, Supply Agreement With Thermo Fisher for Capillary Electrophoresis Sequencing

NEW YORK – Macrogen said on Monday that it has signed a strategic license and supply agreement for capillary electrophoresis sequencing technology with Thermo Fisher Scientific.

The Korean company said it plans to use equipment and reagents from Thermo Fisher and to expand its overseas markets for CE sequencing services. As part of that, it has established laboratories in Spain and in Singapore and plans to open additional labs in Oceania and Europe.

"Macrogen is preparing to take the next big step in the market for [CE sequencing], which has been key to the company's initial growth and is growing rapidly thanks to the expansion of related applications," said Kap-Seok Yang, the company's CEO, in a statement. "Our agreement with global bio market leader Thermo Fisher Scientific will allow Macrogen to pursue global marketing that addresses the ongoing changes in the [CE sequencing] market."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.